Drug Profile

Amoxicillin/clavulanic acid controlled release - Avadel Pharmaceuticals

Alternative Names: Amoxicillin CR/clavulanic acid IR; Co-amoxyclav XR; Long-acting amoxicillin clavulanate

Latest Information Update: 23 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Flamel Technologies
Class 2 ring heterocyclic compounds; Antibacterials; Azetidines; Beta-lactams; Carboxylic acids; Oxazolidinones; Penicillins; Small molecules
Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Infections

Most Recent Events

24 Jan 2017 Discontinued - Phase-I for Infections in France (PO) (Avadel Pharmaceuticals pipeline, January 2017)
23 Oct 2012 Amoxicillin/clavulanic acid controlled release - Flamel Technologies is available for licensing http:www.flamel.com
16 Nov 2010 No development reported - Phase-I for Infections in France (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com